ESR1 and breast cancer: Our study implicates that targeting the estrogen-dependent system xc−, specifically SLC7A11 and SLC3A2, with IKE through induction of ferroptosis in ER+ breast cancer cells, should offer a new therapeutic option for patients with ER+ breast cancer, particularly those with endocrine resistance.